Vitroscope has raised $7 million to expand its live-tissue research platform for studying immune activity, treatment responses, and disease mechanisms over time. The financing consists of a $5 million seed round co-led by Cerberus Ventures and YZR Capital, along with $2 million in non-dilutive funding from the Research Council of Norway.
Other seed investors include Arcas Ventures, Golden Egg Check, Devico Invest, and angel investors Carles Reina, Fàtima Godall, and Oskari Pétas.
The Trondheim, Norway-based company has now raised $8.8 million in total funding.
Vitroscope is developing perfusion technology designed to keep living tissue and organoids viable under controlled conditions for longer periods than conventional static laboratory systems.
Its benchtop system, vitro.alive, combines programmable perfusion with real-time control of oxygen, pH, and temperature, along with live-cell imaging.
The system can run six independent experiments in parallel and works with standard inverted microscopes, allowing researchers to continue using their existing tissue models.
Vitroscope argues that conventional well plates do not adequately reproduce the fluid flow and oxygen conditions required by increasingly sophisticated biological models such as fresh human tissue and organoids.
By maintaining tissue under continuous controlled perfusion, the company aims to enable longer experiments and produce longitudinal biological datasets that may be useful for drug discovery and translational research.
Vitroscope said it and Instant Bio maintained vascularized human brain organoids under perfusion for seven days using vitro.alive.
In separate work, primary human liver cells formed organized tissue on the platform but not in standard well plates.
Another study found that kidney cells lacking AdipoR1, a receptor associated with diabetic kidney disease, showed impaired responses to physiological fluid flow.
The company will use the financing to expand commercial availability of vitro.alive and validate its higher-throughput vitro.scale platform.
Vitro.scale is being designed to support 96 parallel experiments, with customer testing expected to begin in 2027 ahead of a planned 2028 launch.
Vitroscope holds multiple international patents covering its core technologies and methods.
KEY QUOTES:
“We started Vitroscope because living tissue cannot be reduced to a snapshot. Its behavior depends on what is happening around it over time. With vitro.alive, researchers set those conditions themselves and follow how the tissue responds for days. This funding lets us bring this capability to more labs and extend it to higher-throughput experiments with vitro.scale.”
Carlo Kriesi, Co-Founder And CEO Of Vitroscope
“Biology isn’t static, but much of the way we study it still is. Vitroscope is changing that by enabling researchers to observe living tissue over time, generating the rich, longitudinal data that will become increasingly valuable in an AI-driven world.”
Chenny Zhang, Managing Director At Cerberus Ventures
“Drug discovery and development need data that allows researchers to actually predict how patients will respond, and Vitroscope generates it at the source. Its platform is physical AI infrastructure: every experiment on living human tissue produces proprietary, comparable data that compounds over time. For us at YZR Capital, Vitroscope is a key building block in rewiring the pharma value chain, turning cell-level insight into human-relevant evidence long before the first clinical trial.”
Markus Feuerecker, Founding And Managing Partner At YZR Capital
